From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties.
For research use only. We do not sell to patients.
Cedrol is a potent competitive inhibitor of cytochrome P-450(CYP) enzyme. Cedrol plays an anticancer role by inducing cell cycle arrest and Caspase-dependent apoptosis. Cedrol acts as a neutrophil agonist that can desensitize cells to subsequent stimulation of N-formyl peptides. Cedrol prevents neuropathic pain caused by chronic contractile injury by inhibiting oxidative stress and inflammation. In addition, Cedrol has antibacterial, hair loss prevention and anti-anxiety properties[1][2][3][4][5][6][7].
IC50 & Target
CYP2
CYP3
Cellular Effect
Cell Line
Type
Value
Description
References
CTX TNA2
IC50
238.3 μM
Compound: Ced
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against rat CTX TNA2 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cedrol (0-450 μM; 24-72 h) inhibits HT-29 and CT-26 cell proliferation in a dose - and time-dependent manner, with IC50 values of 138.91 and 92.46 µM, respectively[4].
Cedrol (0-225 μM; 0-48 h) induces cell cycle arrest in G0/G1 phase by regulating the expression of cell cycle regulators CDK4 and cyclin D1 and apoptosis through both exogenous (FasL/caspase-8) and endogenous (Bax/caspase-9) pathways in HT-29 and CT-26 cells[4].
Cedrol (0-180 µM; 48 h) combined with 5-FU (HY-90006) significantly decreases HT-29 cell viability[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Reduced the levels of CDK4 and cyclin D1.
Significantly increased the expression levels of FasL/cleaved-caspase-8, Bax/cleaved-caspase-9 and cleaved-caspase-3 in a time- and dose-dependent manner.
In Vivo
Cedrol (150 mg/kg; Subcutaneous injection; Once every two days; 20 days) has antitumor effect in mouse model of colorectal cancer[4].
Cedrol (200-1600 mg/kg; Intraperitoneal injection; Single dose; 30 minutes before the test) exerts anti-anxiety effects in female mice through the 5-hydroxyindoleacetic or dopamine system[5].
Cedrol (50-200 mg/kg; Topical application; 27 days) prevents alopecia in a mouse model of hair loss induced by Cyclophosphamide (HY-17420)[6].
Cedrol (20-40 mg/kg; Intraperitoneal injection; Once a day; 14 days) relieves neuropathic pain by inhibiting oxidative stress and inflammation in a rat model of chronic contractile injury[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Intraperitoneal injection (i.p.); Single dose; 30 min prior to the test
Result:
Exhibited anxiolytic activity on the female mice at dose of 1200-1600 mg/kg.
Increased the level of 5-hydroxytryptamine, decreased the level of dopamine.
Reduced the ratio of 5-hydroxyindoleacetic acid/5-hydroxytryptamine, increased the ratio of 3,4-dihydroxyphenyl acetic acid/dopamine.
Inhibited alopecia in a dose-dependent manner, manifested mild alopecia with 40% suppression at a dose of 200 mg/kg on day 6 of the experiment.
Restored the hair follicles to its nearly normal modality at a dose of 200 mg/kg on day 15 of the experiment.
Promoted hair regrowth on day 11 of the experiment.
Animal Model:
Adult male Wistar rats (220-270 g) with chronic constriction injury (CCI)[7]
Dosage:
20 and 40 mg/kg
Administration:
Intraperitoneal injection (i.p.); once a day for 14 days
Result:
Attenuated the CCI-induced mechanical and thermal hypersensitivity.
Increased the level of total thiol.
Reduced the levels of MDA.
Reduced the levels of TNF-α and IL-6.
DMSO : 110 mg/mL (494.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Preparing Stock Solutions
ConcentrationSolventMass
1 mg
5 mg
10 mg
1 mM
4.4970 mL
22.4850 mL
44.9701 mL
5 mM
0.8994 mL
4.4970 mL
8.9940 mL
10 mM
0.4497 mL
2.2485 mL
4.4970 mL
View the Complete Stock Solution Preparation Table
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day. The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Solubility: 2.75 mg/mL (12.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μLDMSO stock solution (27.5 mg/mL) to 900 μLCorn oil, and mix evenly.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
Dosage
mg/kg
Animal weight (per animal)
g
Dosing volume (per animal)
μL
Number of animals
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO+
%
+
%
Tween-80
+
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO,
. All of co-solvents are available by MedChemExpress (MCE).
, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration:
mg/mL
Method for preparing stock solution:
mg
drug dissolved in
μL
DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take
μL DMSO stock solution, add
μL .
μL , mix evenly, next add
μL Tween 80, mix evenly, then add
μL Saline.
Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution
If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
*Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Powered by Bioz
